[3]
Jones J. The life and work of Guy Newton (1919-1969). Journal of peptide science : an official publication of the European Peptide Society. 2008 May:14(5):545-55. doi: 10.1002/psc.1014. Epub
[PubMed PMID: 18314931]
[4]
El-Shaboury SR, Saleh GA, Mohamed FA, Rageh AH. Analysis of cephalosporin antibiotics. Journal of pharmaceutical and biomedical analysis. 2007 Sep 21:45(1):1-19. doi: 10.1016/j.jpba.2007.06.002. Epub 2007 Jun 9
[PubMed PMID: 17689910]
[5]
Klein NC, Cunha BA. The selection and use of cephalosporins: a review. Advances in therapy. 1995 Mar-Apr:12(2):83-101
[PubMed PMID: 10150326]
Level 3 (low-level) evidence
[6]
Sunjaya DB, Lennon RJ, Shah VH, Kamath PS, Simonetto DA. Prevalence and Predictors of Third-Generation Cephalosporin Resistance in the Empirical Treatment of Spontaneous Bacterial Peritonitis. Mayo Clinic proceedings. 2019 Aug:94(8):1499-1508. doi: 10.1016/j.mayocp.2018.12.036. Epub 2019 Jul 11
[PubMed PMID: 31303428]
[7]
Klein NC, Cunha BA. Third-generation cephalosporins. The Medical clinics of North America. 1995 Jul:79(4):705-19
[PubMed PMID: 7791418]
[8]
Le Saux N, Ronald AR. Role of ceftriaxone in sexually transmitted diseases. Reviews of infectious diseases. 1989 Mar-Apr:11(2):299-309
[PubMed PMID: 2649963]
[9]
Flamm RK, Farrell DJ, Sader HS, Jones RN. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). The Journal of antimicrobial chemotherapy. 2014 Jun:69(6):1589-98. doi: 10.1093/jac/dku025. Epub 2014 Feb 20
[PubMed PMID: 24562613]
[10]
Mosley JF 2nd, Smith LL, Parke CK, Brown JA, Wilson AL, Gibbs LV. Ceftazidime-Avibactam (Avycaz): For the Treatment of Complicated Intra-Abdominal and Urinary Tract Infections. P & T : a peer-reviewed journal for formulary management. 2016 Aug:41(8):479-83
[PubMed PMID: 27504064]
[11]
Chalhoub H, Tunney M, Elborn JS, Vergison A, Denis O, Plésiat P, Kahl BC, Van Bambeke F, Tulkens PM. Avibactam confers susceptibility to a large proportion of ceftazidime-resistant Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients. The Journal of antimicrobial chemotherapy. 2015 May:70(5):1596-8. doi: 10.1093/jac/dku551. Epub 2015 Jan 14
[PubMed PMID: 25587996]
[12]
Buckman SA, Krekel T, Muller AE, Mazuski JE. Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections. Expert opinion on pharmacotherapy. 2016 Dec:17(17):2341-2349
[PubMed PMID: 27758148]
Level 3 (low-level) evidence
[13]
Ross JDC, Brittain C, Cole M, Dewsnap C, Harding J, Hepburn T, Jackson L, Keogh M, Lawrence T, Montgomery AA, Roberts TE, Sprange K, Tan W, Thandi S, White J, Wilson J, Duley L, G-ToG trial team. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet (London, England). 2019 Jun 22:393(10190):2511-2520. doi: 10.1016/S0140-6736(18)32817-4. Epub 2019 May 2
[PubMed PMID: 31056291]
Level 1 (high-level) evidence
[14]
van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, Leib SL, Mourvillier B, Ostergaard C, Pagliano P, Pfister HW, Read RC, Sipahi OR, Brouwer MC, ESCMID Study Group for Infections of the Brain (ESGIB). ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2016 May:22 Suppl 3():S37-62. doi: 10.1016/j.cmi.2016.01.007. Epub 2016 Apr 7
[PubMed PMID: 27062097]
[15]
Margalit I, Lebeaux D, Tishler O, Goldberg E, Bishara J, Yahav D, Coussement J. How do I manage nocardiosis? Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021 Apr:27(4):550-558. doi: 10.1016/j.cmi.2020.12.019. Epub 2021 Jan 5
[PubMed PMID: 33418019]
[16]
Fiore M, Maraolo AE, Leone S, Gentile I, Cuomo A, Schiavone V, Bimonte S, Pace MC, Cascella M. Spontaneous peritonitis in critically ill cirrhotic patients: a diagnostic algorithm for clinicians and future perspectives. Therapeutics and clinical risk management. 2017:13():1409-1414. doi: 10.2147/TCRM.S144262. Epub 2017 Oct 16
[PubMed PMID: 29081656]
Level 3 (low-level) evidence
[17]
Tripathi N, Koirala N, Kato H. Increasing Resistance to Third-Generation Cephalosporins in Spontaneous Bacterial Peritonitis. Mayo Clinic proceedings. 2020 Apr:95(4):828-829. doi: 10.1016/j.mayocp.2020.01.005. Epub
[PubMed PMID: 32247358]
[18]
McPherson C, Liviskie C, Zeller B, Nelson MP, Newland JG. Antimicrobial Stewardship in Neonates: Challenges and Opportunities. Neonatal network : NN. 2018 Mar 1:37(2):116-123. doi: 10.1891/0730-0832.37.2.116. Epub
[PubMed PMID: 29615159]
[19]
Maraolo AE, Cascella M, Corcione S, Cuomo A, Nappa S, Borgia G, De Rosa FG, Gentile I. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art. Expert review of anti-infective therapy. 2017 Sep:15(9):861-871. doi: 10.1080/14787210.2017.1367666. Epub 2017 Aug 18
[PubMed PMID: 28803496]
[20]
Leone S, Cascella M, Pezone I, Fiore M. New antibiotics for the treatment of serious infections in intensive care unit patients. Current medical research and opinion. 2019 Aug:35(8):1331-1334. doi: 10.1080/03007995.2019.1583025. Epub 2019 Mar 22
[PubMed PMID: 30760041]
Level 3 (low-level) evidence
[21]
van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Jul 15:63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20
[PubMed PMID: 27098166]
[22]
Auer GK, Weibel DB. Bacterial Cell Mechanics. Biochemistry. 2017 Jul 25:56(29):3710-3724. doi: 10.1021/acs.biochem.7b00346. Epub 2017 Jul 11
[PubMed PMID: 28666084]
[23]
Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS microbiology reviews. 2008 Mar:32(2):234-58. doi: 10.1111/j.1574-6976.2008.00105.x. Epub 2008 Feb 11
[PubMed PMID: 18266856]
[24]
Sarkar P, Yarlagadda V, Ghosh C, Haldar J. A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics. MedChemComm. 2017 Mar 1:8(3):516-533. doi: 10.1039/c6md00585c. Epub 2017 Jan 26
[PubMed PMID: 30108769]
[25]
García-Rodríguez JA, Muñoz Bellido JL, García Sánchez JE. Oral cephalosporins: current perspectives. International journal of antimicrobial agents. 1995 Jul:5(4):231-43
[PubMed PMID: 18611674]
Level 3 (low-level) evidence
[26]
Schmidt S, Röck K, Sahre M, Burkhardt O, Brunner M, Lobmeyer MT, Derendorf H. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrobial agents and chemotherapy. 2008 Nov:52(11):3994-4000. doi: 10.1128/AAC.00427-08. Epub 2008 Sep 8
[PubMed PMID: 18779351]
[27]
Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Annals of the American Thoracic Society. 2014 Mar:11(3):425-34. doi: 10.1513/AnnalsATS.201311-395FR. Epub
[PubMed PMID: 24673698]
[28]
O'Neill E, Humphreys H, Phillips J, Smyth EG. Third-generation cephalosporin resistance among Gram-negative bacilli causing meningitis in neurosurgical patients: significant challenges in ensuring effective antibiotic therapy. The Journal of antimicrobial chemotherapy. 2006 Feb:57(2):356-9
[PubMed PMID: 16368699]
[29]
Jin HE, Jin SE, Maeng HJ. Recent bioanalytical methods for quantification of third-generation cephalosporins using HPLC and LC-MS(/MS) and their applications in pharmacokinetic studies. Biomedical chromatography : BMC. 2014 Nov:28(11):1565-87. doi: 10.1002/bmc.3330. Epub 2014 Oct 8
[PubMed PMID: 25294385]
[30]
Chin NX, Neu HC. Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism. Diagnostic microbiology and infectious disease. 1984 Jun:2(3 Suppl):21S-31S
[PubMed PMID: 6086215]
[31]
Rockoff SD, Blumenfrucht MJ, Irwin RJ Jr, Eng RH. Vitamin K supplementation during prophylactic use of cefoperazone in urologic surgery. Infection. 1992 May-Jun:20(3):146-8
[PubMed PMID: 1644490]
[32]
Fekety FR. Safety of parenteral third-generation cephalosporins. The American journal of medicine. 1990 Apr 9:88(4A):38S-44S
[PubMed PMID: 2183609]
[33]
Plosker GL, Foster RH, Benfield P. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections. PharmacoEconomics. 1998 Jan:13(1 Pt 1):91-106
[PubMed PMID: 10175990]
[34]
Parmar PM, Solanki VV, Barvaliya MJ, Chavada BC, Tripathi CR. Cephalosporins Associated Pseudomembraneous Colitis in an Elderly Male Patient - A Case Report. Current drug safety. 2017:12(3):205-207. doi: 10.2174/1574886312666170616091217. Epub
[PubMed PMID: 28625146]
Level 3 (low-level) evidence
[35]
Macy E, Goldberg B, Poon KY. Use of commercial anti-penicillin IgE fluorometric enzyme immunoassays to diagnose penicillin allergy. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2010 Aug:105(2):136-41. doi: 10.1016/j.anai.2010.06.014. Epub
[PubMed PMID: 20674824]
[36]
Grossjohann B, Eichler P, Greinacher A, Santoso S, Kroll H. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion. 2004 Jul:44(7):1033-40
[PubMed PMID: 15225244]
[37]
Kim KB, Kim SM, Park W, Kim JS, Kwon SK, Kim HY. Ceftiaxone-induced neurotoxicity: case report, pharmacokinetic considerations, and literature review. Journal of Korean medical science. 2012 Sep:27(9):1120-3. doi: 10.3346/jkms.2012.27.9.1120. Epub 2012 Aug 22
[PubMed PMID: 22969263]
Level 3 (low-level) evidence
[38]
Abe S. A case of ceftriaxone-associated biliary pseudolithiasis in an elderly patient with renal dysfunction. IDCases. 2017:9():62-64. doi: 10.1016/j.idcr.2017.06.007. Epub 2017 Jun 27
[PubMed PMID: 28706853]
Level 3 (low-level) evidence
[39]
Harr T,French LE, Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet journal of rare diseases. 2010 Dec 16;
[PubMed PMID: 21162721]
[40]
Khan DA, Banerji A, Bernstein JA, Bilgicer B, Blumenthal K, Castells M, Ein D, Lang DM, Phillips E. Cephalosporin Allergy: Current Understanding and Future Challenges. The journal of allergy and clinical immunology. In practice. 2019 Sep-Oct:7(7):2105-2114. doi: 10.1016/j.jaip.2019.06.001. Epub
[PubMed PMID: 31495420]
Level 3 (low-level) evidence
[42]
Chaudhry SB, Veve MP, Wagner JL. Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity. Pharmacy (Basel, Switzerland). 2019 Jul 29:7(3):. doi: 10.3390/pharmacy7030103. Epub 2019 Jul 29
[PubMed PMID: 31362351]
[43]
Martin E, Fanconi S, Kälin P, Zwingelstein C, Crevoisier C, Ruch W, Brodersen R. Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study. European journal of pediatrics. 1993 Jun:152(6):530-4
[PubMed PMID: 8335024]
[44]
Bradley JS, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics. 2009 Apr:123(4):e609-13. doi: 10.1542/peds.2008-3080. Epub 2009 Mar 16
[PubMed PMID: 19289450]
[45]
Saum LM, Balmat RP. Ceftriaxone Potentiates Warfarin Activity Greater Than Other Antibiotics in the Treatment of Urinary Tract Infections. Journal of pharmacy practice. 2016 Apr:29(2):121-4. doi: 10.1177/0897190014544798. Epub 2014 Aug 3
[PubMed PMID: 25092605]
[46]
Bar-Oz B, Bulkowstein M, Benyamini L, Greenberg R, Soriano I, Zimmerman D, Bortnik O, Berkovitch M. Use of antibiotic and analgesic drugs during lactation. Drug safety. 2003:26(13):925-35
[PubMed PMID: 14583068]
[47]
Blanco JD, Jorgensen JH, Castaneda YS, Crawford SA. Ceftazidime levels in human breast milk. Antimicrobial agents and chemotherapy. 1983 Mar:23(3):479-80
[PubMed PMID: 6342531]
[48]
Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P & T : a peer-reviewed journal for formulary management. 2015 Apr:40(4):277-83
[PubMed PMID: 25859123]
[49]
Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. The Journal of antimicrobial chemotherapy. 2005 Jul:56(1):52-9
[PubMed PMID: 15917288]
[50]
Guri A, Flaks-Manov N, Ghilai A, Hoshen M, Flidel Rimon O, Ciobotaro P, Zimhony O. Third-generation cephalosporin resistant Enterobacteriaceae in neonates and young infants: impact and outcome. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2022 Aug:35(16):3119-3123. doi: 10.1080/14767058.2020.1812572. Epub 2020 Sep 2
[PubMed PMID: 32878507]
[51]
Principe L, Bernasconi OJ, Viaggi V, Campos-Madueno EI, Endimiani A, Luzzaro F. Emergence of Haemophilus parainfluenzae resistant to third-generation cephalosporins in Italy: potential role of PBP3 and PBP5 substitutions in high-level resistance. International journal of antimicrobial agents. 2020 Nov:56(5):106159. doi: 10.1016/j.ijantimicag.2020.106159. Epub 2020 Sep 9
[PubMed PMID: 32919010]
[52]
Carrié C, Bardonneau G, Petit L, Ouattara A, Gruson D, Pereira B, Biais M. Piperacillin-tazobactam should be preferred to third-generation cephalosporins to treat wild-type inducible AmpC-producing Enterobacterales in critically ill patients with hospital or ventilator-acquired pneumonia. Journal of critical care. 2020 Apr:56():6-11. doi: 10.1016/j.jcrc.2019.11.005. Epub 2019 Nov 13
[PubMed PMID: 31765910]
[53]
Duceac LD, Calin G, Eva L, Marcu C, Bogdan Goroftei ER, Dabija MG, Mitrea G, Luca AC, Hanganu E, Gutu C, Stafie L, Banu EA, Grierosu C, Iordache AC. Third-Generation Cephalosporin-Loaded Chitosan Used to Limit Microorganisms Resistance. Materials (Basel, Switzerland). 2020 Oct 27:13(21):. doi: 10.3390/ma13214792. Epub 2020 Oct 27
[PubMed PMID: 33120990]
[54]
Durand C, Boudet A, Lavigne JP, Pantel A. Evaluation of Two Methods for the Detection of Third Generation Cephalosporins Resistant Enterobacterales Directly From Positive Blood Cultures. Frontiers in cellular and infection microbiology. 2020:10():491. doi: 10.3389/fcimb.2020.00491. Epub 2020 Sep 11
[PubMed PMID: 33014900]
[56]
Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clinical microbiology reviews. 2005 Oct:18(4):657-86
[PubMed PMID: 16223952]
[57]
Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Archives of internal medicine. 2002 Jan 28:162(2):185-90
[PubMed PMID: 11802752]
[58]
Laws M, Shaaban A, Rahman KM. Antibiotic resistance breakers: current approaches and future directions. FEMS microbiology reviews. 2019 Sep 1:43(5):490-516. doi: 10.1093/femsre/fuz014. Epub
[PubMed PMID: 31150547]
Level 3 (low-level) evidence